AASLD Practice Guideline

You have full text access to this OnlineOpen article

Management of hepatocellular carcinoma: An update †‡

  1. Jordi Bruix1,§,*,
  2. Morris Sherman2

Article first published online: 2 MAR 2011

DOI: 10.1002/hep.24199

Issue

Hepatology

Hepatology

Volume 53, Issue 3, pages 1020–1022, March 2011

Additional Information

How to Cite

Bruix, J. and Sherman, M. (2011), Management of hepatocellular carcinoma: An update . Hepatology, 53: 1020–1022. doi: 10.1002/hep.24199

Author Information

  1. 1

    Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

  2. 2

    University of Toronto and University Health Network, Toronto, Canada

  1. §

    fax: (34) 93-227-9803

*Hospital Clinic, University of Barcelona, IDIPAPS, CIBERehd, c/Villarroel 170, Barcelona 08036, Catalonia, Spain

  1. †

    Potential conflict of interest: Dr. Bruix advises, consults for, serves on the speaker's bureau of, and received grants from Bayer. Dr. Bruix consults for Biocompatibles, GlaxoSmithKline, Kowa, Novartis, and Arqule. Dr. Bruix also advises and consults for Bristol-Myers Squibb. Dr. Sherman serves on the speakers' bureau of Bayer

  2. ‡

    Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

  3. §

    fax: (34) 93-227-9803

Publication History

  1. Issue published online: 2 MAR 2011
  2. Article first published online: 2 MAR 2011
  3. Accepted manuscript online: 19 JAN 2011 09:02AM EST
  4. Manuscript Accepted: 8 JAN 2011
  5. Manuscript Received: 3 JAN 2011

Funded by

  • Unknown funding agency

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

No abstract is available for this article.

View Full Article (HTML) Get PDF (217K)